undamentalytics Newsletter
Sign in

Omniab, Inc. (OABI) stock

Add to watchlist

Add holding +

NASDAQ: OABI Nasdaq Life Sciences Tools & Services Next results ~January 28, 2027

C+ Fundamentals grade

Omniab, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$1.1

Revenue-to-maturity model

Base case. Range ~$0.9–$1.2. Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Omniab, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 3 selling2 purchases and 12 sales by directors and officers, last 12 monthsInsider trades
  • Funds76 adding, 48 cuttingOf 21 active managers that changed their stake, 16 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Omniab files

10-Q filed October 30: Omniab

Model value +1.9%

Omniab posted revenue of $40m for the twelve months to September 2026, up 90.6% on a year earlier and an acceleration from the 67.0% growth recorded a quarter earlier. Among the 46 life sciences tools & services companies we cover, that growth rate ranks first. Free-cash-flow margin improved sharply, rising to 5.9% from -167.1% a year earlier, while the operating margin, though still deeply negative, widened to -115.9% from -327.5%. Existing holders face further dilution, with the diluted share count up 19.2% on a year earlier. Our model value edges up from $1.07 to $1.09 a share, which remains well below the current share price of $5.11.

Source: 10-Q filed October 30, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (2)

10-Q filed August 6: Omniab

Omniab's revenue over the twelve months to June 2026 reached $40m, a 90.6% rise on the year before and an acceleration from the 67.0% growth seen a quarter earlier. Among the 46 life sciences tools & services companies we cover, that pace ranks first. Profitability also improved: free-cash-flow margin climbed to 5.9% from -167.1% a year earlier, while the operating margin widened to -115.9% from -327.5%. Shareholders should note that the diluted share count grew 19.2% over the year, a dilutive effect on existing holders. Taken together, these shifts lift the fundamentals grade from D to C+. Still, our revenue-to-maturity cash-flow model puts fair value at just $1.07 a share, far below the current price of $5.28.

10-Q on SEC EDGAR

Where Omniab stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $38m, up 67.0% on a year earlier, faster than the 8.2% growth a quarter earlier. That growth ranks 1 of 46 among the life sciences tools & services companies we cover. Free-cash-flow margin rose to -47.2% from -139.1% a year earlier. Operating margin widened to -125.8% from -307.1%. The diluted share count is up 19.3% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 2 financial-health checks.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 28, 2027 (estimated)

Omniab, Inc.'s trailing-twelve-month revenue grew 90.6% year on year, with a free-cash-flow margin of 5.9%. Where it stands out: revenue growth of 90.6% ranks 1 of 54 life sciences tools & services companies we cover. Where it lags: stock pay as % of revenue of 32.7% ranks 48 of 53 life sciences tools & services companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 90.6% (+23.6pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 90.6% over the last 12 months, against a median of 6.9% for life sciences tools & services companies we cover.
  • Growth speeding up. The growth rate is 23.6 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 211.6 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -115.9%: costs exceed revenue.
  • Heavy stock-based pay. Stock pay equals 32.7% of revenue, against a median of 4.4% for life sciences tools & services companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 19.2% in a year.
  • High sales multiple. The shares trade at 16 times revenue while operating margins remain thin.
  • Volatile shares. Over the past year the shares showed annualised volatility of 76% and a beta of 1.3 against the S&P 500.
  • Short interest rising. Shares sold short rose 20% in a month to 6.4% of tradable shares.

Latest results: FY2026 Q3

Filed October 30, 2026
Earnings per share
-$0.12 against an average estimate of -$0.13: beat by 7.7%
Revenue
$4m, up 78.3% on a year earlier
Share reaction
-2.7% in the first session after the results on October 30, 2026, against -2.2% for the S&P 500
Next report
October 30, 2026; average EPS estimate -$0.14

Omniab's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.4%
  • 1 week+10.4%
  • 1 month+4.5%
  • This year+175.1%
  • 1 year+228.4%
  • 5 years-48.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$40.2M
Operating margin
-115.9%
Net margin
-108.1%
EPS (TTM, diluted)
$-0.34

Growth

Revenue growth
+90.6%
Change in growth rate
+23.6 pts
Share count change
+19.2%

Cash

Free cash flow (TTM)
$2.4M
FCF margin
5.9%
Stock pay % of revenue
32.7%

Earnings

Last results
October 30, 2026
Next results (est.)
January 28, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Results
  3. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Omniab, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Omniab, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.3 ~$0.2–$0.4 Left out: out of range vs price (0.05x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.9 ~$0.7–$1.9 Left out: out of range vs price (0.17x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$1.1 ~$0.9–$1.2 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$1.1 ~$0.9–$1.2 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Omniab, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$10.00$3.60$6.17$3.54$1.85$5.09
Market value$826m$307m$615m$362m$210m$655m
+ Net debt (− = net cash)$0−$33m−$16m−$28m−$26m−$23m
Enterprise value$826m$274m$599m$335m$185m$632m
Multiples
Price / sales 23.8x5.2x18.0x13.7x11.3x16.3x
Price / earnings ——————
Price / free cash flow ——n/m——n/m
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.37 +36% $35m +88%
Next −$0.29 +20% $44m +25%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −12.0% on 90 days ago. In the last 30 days, 5 analysts raised Omniab, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Omniab, Inc., last 90 days
−$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.42 Current fiscal year, 60 days ago: −$0.37 Current fiscal year, 30 days ago: −$0.37 Current fiscal year, 7 days ago: −$0.37 Current fiscal year, Now: −$0.37 −$0.37 Next fiscal year, 90 days ago: −$0.32 Next fiscal year, 60 days ago: −$0.30 Next fiscal year, 30 days ago: −$0.29 Next fiscal year, 7 days ago: −$0.29 Next fiscal year, Now: −$0.29 −$0.29

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.42−$0.32
60 days ago −$0.37−$0.30
30 days ago −$0.37−$0.29
7 days ago −$0.37−$0.29
Now −$0.37−$0.29

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$0.13 −$0.12 +7.7%
Jun 2026 −$0.13 −$0.05 +60.8%
Mar 2026 −$0.10 −$0.06 +37.9%
Dec 2025 −$0.09 −$0.11 −25.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

7 analysts, Oct 2026
Buy7100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202677
  2. Sep 202677
  3. Aug 202677

Counts of recommendations published by analysts covering Omniab, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.4%
of tradable shares
Days to cover
6.88
at average volume
Short interest, 1 month
+20%
to October 15, 2026
Held by institutions
53%
of shares
Held by insiders
15.3%
of shares
Employees
89
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +228.4%

$1.55 on October 31, 2025 to $5.09

ThenNowEffect
Revenue (last 12 months) $23m $38m +67.0%
P/S multiple 7.1x 16.5x +134.5%
Share count 105m 125m −16.2%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +8.3%

$4.70 on November 3, 2023 to $5.09

ThenNowEffect
Revenue (last 12 months) $66m $38m −41.8%
P/S multiple 6.7x 16.5x +148.4%
Share count 94m 125m −25.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
OABI−64%+71%−43%−48%+175%
Industry peers (median)−51%−3%−13%−2%+15%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
OABI58%58%25%42%36%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
OABI−80%−29%−48%−68%−34%
S&P 500−25%−10%−8%−19%−9%

Worst fall since September 30, 2021: 88% from October 17, 2022 to May 29, 2025. Getting back needed a 725% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.36 – $5.28
From 52-week high
−3.6%
vs 50-day average
+9.0%
vs 200-day average
+87.2%
Volatility (1 year)
76%
Beta vs S&P 500
1.30

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±12.1%
After a week
9 up, 2 down
typical move ±17.4%
After a month
5 up, 6 down
typical move ±27.8%
Results releasedNext dayS&P 500 next day5 days21 days
October 30, 2026 −2.7% −2.2% — —
August 6, 2026 +51.7% +0.5% +69.0% +113.3%
May 7, 2026 +16.1% +0.5% +53.1% +59.4%
March 4, 2026 +15.6% +0.1% +13.0% −11.0%
November 4, 2025 −3.7% −0.8% +8.8% +33.1%
August 6, 2025 −7.8% +0.7% +0.5% −16.2%
May 8, 2025 −5.9% +0.6% +1.3% −2.0%
March 18, 2025 −19.9% 0.0% −23.0% −44.2%
November 12, 2024 −11.5% −0.3% −16.5% −13.0%
August 8, 2024 +4.4% +2.8% +3.9% +1.2%
May 9, 2024 +3.1% +0.7% +0.2% +1.3%
March 20, 2024 −2.5% +1.3% +2.3% −11.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Omniab, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Omniab, Inc.
$10M $20M $30M $40M $50M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $34.2M Revenue (TTM), FY24 Q1: $21M Revenue (TTM), FY24 Q2: $21.7M Revenue (TTM), FY24 Q3: $20.4M Revenue (TTM), FY24 Q4: $26.4M Revenue (TTM), FY25 Q1: $26.7M Revenue (TTM), FY25 Q2: $23M Revenue (TTM), FY25 Q3: $21.1M Revenue (TTM), FY25 Q4: $18.7M Revenue (TTM), FY26 Q1: $28.9M Revenue (TTM), FY26 Q2: $38.5M Revenue (TTM), FY26 Q3: $40.2M $40.2M

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $34.2M
FY24 Q1 $21M
FY24 Q2 $21.7M
FY24 Q3 $20.4M
FY24 Q4 $26.4M
FY25 Q1 $26.7M
FY25 Q2 $23M
FY25 Q3 $21.1M
FY25 Q4 $18.7M
FY26 Q1 $28.9M
FY26 Q2 $38.5M
FY26 Q3 $40.2M
Revenue growth, TTM YoY Omniab, Inc.
-100% -50% 0% 50% 100% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: -42.2% Revenue growth, TTM YoY, FY24 Q1: -68.3% Revenue growth, TTM YoY, FY24 Q2: -67.2% Revenue growth, TTM YoY, FY24 Q3: -68.4% Revenue growth, TTM YoY, FY24 Q4: -22.8% Revenue growth, TTM YoY, FY25 Q1: 27.1% Revenue growth, TTM YoY, FY25 Q2: 6.0% Revenue growth, TTM YoY, FY25 Q3: 3.4% Revenue growth, TTM YoY, FY25 Q4: -29.3% Revenue growth, TTM YoY, FY26 Q1: 8.2% Revenue growth, TTM YoY, FY26 Q2: 67.0% Revenue growth, TTM YoY, FY26 Q3: 90.6% 90.6%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -42.2%
FY24 Q1 -68.3%
FY24 Q2 -67.2%
FY24 Q3 -68.4%
FY24 Q4 -22.8%
FY25 Q1 27.1%
FY25 Q2 6.0%
FY25 Q3 3.4%
FY25 Q4 -29.3%
FY26 Q1 8.2%
FY26 Q2 67.0%
FY26 Q3 90.6%
Operating margin (TTM) Omniab, Inc.
-400% -300% -200% -100% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -203.2% Operating margin (TTM), FY24 Q1: -396.8% Operating margin (TTM), FY24 Q2: -370.2% Operating margin (TTM), FY24 Q3: -391.1% Operating margin (TTM), FY24 Q4: -282.3% Operating margin (TTM), FY25 Q1: -264.7% Operating margin (TTM), FY25 Q2: -307.1% Operating margin (TTM), FY25 Q3: -327.5% Operating margin (TTM), FY25 Q4: -369.5% Operating margin (TTM), FY26 Q1: -200.3% Operating margin (TTM), FY26 Q2: -125.8% Operating margin (TTM), FY26 Q3: -115.9% -115.9%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -203.2%
FY24 Q1 -396.8%
FY24 Q2 -370.2%
FY24 Q3 -391.1%
FY24 Q4 -282.3%
FY25 Q1 -264.7%
FY25 Q2 -307.1%
FY25 Q3 -327.5%
FY25 Q4 -369.5%
FY26 Q1 -200.3%
FY26 Q2 -125.8%
FY26 Q3 -115.9%
FCF margin (TTM) Omniab, Inc.
-300% -200% -100% 0% 100% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 2.1% FCF margin (TTM), FY24 Q1: -212.4% FCF margin (TTM), FY24 Q2: -215.6% FCF margin (TTM), FY24 Q3: -229.6% FCF margin (TTM), FY24 Q4: -157.4% FCF margin (TTM), FY25 Q1: -148.3% FCF margin (TTM), FY25 Q2: -139.1% FCF margin (TTM), FY25 Q3: -167.1% FCF margin (TTM), FY25 Q4: -198.3% FCF margin (TTM), FY26 Q1: -89.9% FCF margin (TTM), FY26 Q2: -47.2% FCF margin (TTM), FY26 Q3: 5.9% 5.9%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 2.1%
FY24 Q1 -212.4%
FY24 Q2 -215.6%
FY24 Q3 -229.6%
FY24 Q4 -157.4%
FY25 Q1 -148.3%
FY25 Q2 -139.1%
FY25 Q3 -167.1%
FY25 Q4 -198.3%
FY26 Q1 -89.9%
FY26 Q2 -47.2%
FY26 Q3 5.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 35 59 34 26 19 40
EBITDA −19 −8 −50 −51 −47 −37
Operating income −36 −27 −69 −75 −69 −47
Net income −27 −22 −51 −62 −65 −43
Diluted EPS −$0.33 −$0.26 −$0.51 −$0.61 −$0.57 −$0.34
Growth (year on year)
Revenue — +70.0% −42.2% −22.8% −29.3% +90.6%
Margins
EBITDA margin −55.7% −14.2% −146.1% −192.9% −252.9% −92.5%
Operating margin −102.5% −45.1% −203.2% −282.3% −369.5% −115.9%
Net margin −77.8% −37.8% −148.2% −235.1% −347.0% −108.1%
Free-cash-flow margin −28.0% −35.1% 2.1% −157.4% −198.3% 5.9%
Cash flow
Cash from operations −6 −4 2 −40 −36 3
Capital spending 4 17 2 2 1 0
Free cash flow −10 −21 1 −42 −37 2
Stock-based pay 15 18 25 21 16 13
Free cash flow after stock pay −25 −39 −24 −63 −53 −11
Balance sheet
Cash 0 33 16 28 26 23
Total debt 0 0 0 0 0 0
Net debt (negative = net cash) 0 −33 −16 −28 −26 −23
Diluted shares 83m 85m 100m 102m 114m 129m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · September 30, 2026
What it owns · $291m
Short-term assets $71mLonger-term assets $220m
What it owes, and who funded it · $291m
Short-term liabilities $17mLonger-term liabilities $25mShareholders' equity $249m
  • Short-term assets cover short-term liabilities $71m of assets due within a year against $17m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $71m short-term assets against $25m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Omniab, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+19.2%
year over year
R&D spending
106.2%
of revenue
Days sales outstanding
23 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated OABI TKNO RPID MXCT BNGO CSBR Median
Revenue, last 12 months $40m $44m $35m $31m $30m $61m $229m
Revenue growth, last 12 months 90.6% 12.3% 16.1% −13.2% 10.0% 6.7% 6.9%
Revenue growth, 3-year average −14.7% 3.7% 22.5% −8.6% −1.4% 4.8% 2.9%
Revenue growth, latest quarter 78.3% 18.5% 10.9% −14.5% 21.4% 8.8% 8.5%
Gross margin — 34.6% — 79.2% 47.5% 49.8% 51.9%
Operating margin −115.9% −36.2% −141.5% −134.6% −106.7% −1.7% −14.3%
Operating margin, 3-year average −278.2% −61.6% −171.1% −128.7% −293.0% −1.2% −22.4%
Net margin −108.1% −38.4% −145.6% −114.8% −106.6% −1.8% −16.1%
Cash from operations / revenue 6.6% −14.4% −113.9% −74.0% −67.9% −9.2% 1.3%
Free-cash-flow margin 5.9% −16.8% −114.8% −76.1% −67.9% −10.1% −2.2%
Free-cash-flow margin, 3-year average −130.3% −32.0% −143.5% −79.7% −150.1% −0.4% 0.6%
Stock pay / revenue 32.7% 6.7% 12.3% 16.0% 11.6% 3.0% 4.4%
Change in share count 19.2% 1.0% 4.4% 1.0% — −2.4% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 90.6% 6.9% 1 of 54
Change in growth rate Growth +23.6pp +0.4pp 2 of 54
Operating margin Profitability -115.9% -14.3% 43 of 52
Net margin Profitability -108.1% -12.2% 45 of 54
Free-cash-flow margin Cash generation 5.9% -1.3% 21 of 54
Stock pay as % of revenue Cash generation 32.7% 4.4% 48 of 53
Change in share count Balance sheet 19.2% 1.0% 40 of 46
Days sales outstanding Balance sheet 23 days 62 days 4 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
License and Milestone Revenue $9.8M 52.3% ▼ 29.5%
Services $7.3M 38.9% ▼ 39.2%
Royalty $878,000 4.7% ▲ 52.4%
X Ploration Revenue $754,000 4.0% —

From Omniab, Inc.'s 10-K filed March 4, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$145M
Institutions reporting
130
Shares held vs prior quarter
▲ 5.5%
Positions opened / closed
20 / 16

Top buyers and sellers, Q2 2026: 76 institutions bought and 48 sold ; the biggest buyer was Nomura Holdings Inc (+4.3M shares) and the biggest seller Whitefort Capital Management, LP (−4.0M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Whitefort Capital Management, LP $25.2M 10.2M 17.4% ▼ 27.9%
Blackrock, Inc. $21.9M 8.9M 15.1% ▲ 9.8%
Nomura Holdings Inc $12.4M 5.0M 8.6% ▲ 613.2%
Cadian Capital Management, LP $10.4M 4.2M 7.2% ▲ 1.3%
Vanguard Capital Management LLC $9.5M 3.9M 6.6% ▼ 3.5%
Geode Capital Management, LLC $7.1M 2.9M 4.9% ▼ 1.4%
Rice Hall James & Associates, LLC $6.4M 2.6M 4.4% ▲ 2.5%
Private Management Group Inc $5.8M 2.3M 4.0% ▼ 3.5%
State Street Corp $5.2M 2.1M 3.6% ▲ 3.2%
Dimensional Fund Advisors LP $3.1M 1.3M 2.1% ▼ 27.7%
Towerview LLC $2.9M 1.2M 2.0% ▲ 18.0%
Vanguard Portfolio Management LLC $2.4M 980K 1.7% ▲ 8.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Omniab, Inc.'s complete shareholder register. Values are as reported by the filers ; 3 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $107,707 2 trades by 1 insider, last 12 months Insider sales History → $283,036 12 trades by 3 insiders · 0% under pre-set plans
Net ▼ $175,329 net selling
Insider Date Trade Shares Price Value
Berkman Charles S Chief Legal Officer April 7, 2026 Sell 7,157 $1.49 $10,664
Gustafson Kurt A Executive VP, Finance and CFO April 7, 2026 Sell 6,913 $1.49 $10,300
Foehr Matthew W President and CEO April 7, 2026 Sell 19,244 $1.49 $28,674
Foehr Matthew W President and CEO February 18, 2026 Sell 30,843 $1.71 $52,742
Gustafson Kurt A Executive VP, Finance and CFO February 18, 2026 Sell 9,301 $1.71 $15,905
Berkman Charles S Chief Legal Officer February 18, 2026 Sell 9,673 $1.71 $16,541
Berkman Charles S Chief Legal Officer February 17, 2026 Sell 6,990 $1.70 $11,883
Gustafson Kurt A Executive VP, Finance and CFO February 17, 2026 Sell 6,828 $1.70 $11,608
Foehr Matthew W President and CEO February 17, 2026 Sell 20,754 $1.70 $35,282
Foehr Matthew W President and CEO December 8, 2025 Sell 13,666 $1.96 $26,785
Gustafson Kurt A Executive VP, Finance and CFO December 8, 2025 Sell 23,922 $1.96 $46,887
Berkman Charles S Chief Legal Officer December 8, 2025 Sell 8,044 $1.96 $15,766

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 28, 2027 estimated from the company's past filing pattern, not announced

  • October 30, 2026
  • August 6, 2026
  • May 7, 2026
  • March 4, 2026
  • November 4, 2025
  • August 6, 2025

Recent SEC filings

Data status

When each part of this page on Omniab, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Omniab, Inc. in brief

What does Omniab, Inc. do?
Omniab, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Omniab, Inc.'s stock ticker?
Omniab, Inc. trades under the ticker OABI on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Omniab, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Omniab, Inc. reported revenue of $40.2M, 90.6% higher than a year earlier, according to its SEC filings.
What is Omniab, Inc.'s free cash flow?
Omniab, Inc.'s free-cash-flow margin is 5.9% of revenue over the trailing twelve months, ranking 21 of the 54 life sciences tools & services companies we cover.
Who are Omniab, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Whitefort Capital Management, LP, Blackrock, Inc. and Nomura Holdings Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Omniab, Inc.'s market cap?
On November 2, 2026, Omniab, Inc.'s market capitalisation was about $655M and net debt of -$22.9M. Market figures come from third-party market data and may be delayed.
Who are Omniab, Inc.'s competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Omniab, Inc. are Alpha Teknova, Inc., Rapid Micro Biosystems, Inc., Maxcyte, Inc., Bionano Genomics, Inc. and Champions Oncology, Inc. The side-by-side comparison below sets their revenue, margins and growth against Omniab, Inc.'s.
Are insiders buying or selling Omniab, Inc. stock?
Over the last 12 months, Omniab, Inc.'s directors and officers reported 2 open-market purchases and 12 sales on Form 4. The insider trading page charts every trade.
When is Omniab, Inc.'s next earnings date?
Around January 28, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Omniab, Inc. announces its own schedule.